Analysis of the Clinical Characteristics of Malignant Tumor Patients with Rheumatic Symptoms and Rheumatic Disease Combined with Malignant Tumor Patients
Abstract
Objective: We study the relationship between rheumatic immune disease and malignant tumor to provide the basis for clinical diagnosis and treatment. Methods: We selected 53 patients who were hospitalized in our department from January 2013 to February 2020, including 26 patients with rheumatic immune disease combined with malignant tumor and 27 patients with malignant tumor with rheumatic symptoms. We retrospectively analyzed the relationship between gender, age, main clinical manifestations, tumor system distribution, metastasis rate, rheumatic immune disease type and tumor type. Results: Among the patients with rheumatic immune disease complicated with tumor, 26.1% were male and 66.7% were female. Among the tumor patients with rheumatic symptoms, 73.9% were male and 33.3% were female. There was a significant difference in gender composition between the two groups. Among the patients with rheumatic immune disease complicated with tumor, respiratory system tumor was the highest. Among the tumor patients with rheumatic symptoms, the incidence of hematological tumors was the highest. The distribution of tumor system was different between the two groups. The proportion of metastatic tumor in patients with rheumatic symptoms is higher than that in patients with rheumatic immune disease combined with malignant tumor. The percentage of concurrent tumor in three diseases in the same period was 0.363% for rheumatoid arthritis, 2.02% for polymyositis/ dermatomyositis and 0.24% for Sjogren's syndrome. This study shows that patients with polymyositis/ dermatomyositis are more likely to develop malignant tumors. Conclusion: There were significant differences in gender composition, distribution of tumor system and the proportion of metastatic tumor between patients with rheumatic immune disease complicated with malignant tumor and patients with rheumatic symptoms, and malignant tumor was more common in patients with polymyositis/ dermatomyositis.
References
[2] Wang HL, Zhou YM, Zhu GZ, etal. Malignancy as a comorbidity in rheumatic diseases: a retrospective hospital-based study[J] . Clinical Rheumatology, 2018, 37(1):81-85.
[3] Fam AG．Paraneoplastic rheumatic syndromes[J]. Baillieres Best Pract Ｒes Clin Ｒheumatol, 2000, 14(3): 515-533．
[4] Shankaran V, Ikeda H, Bruce AT, et al. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity[J]. Nature, 2001, 410(6832): 1107-1111.
[5] Francescone R,Hou V,Microbiome.inflammation,and cancer[J].Cancer journal (Sudbury,Mass.), 2014,20(3):181-189.
[6] Beyaert R, Beaugerie L, Van Assche G, et al.Cancer risk in immune-mediated inflammatory diseases (IMID) [J]. Molecular cancer, 2013,12(1):98-100.
[7] Cutolo M, Paolino S. Possible contribution of chronic inflammation in the induction of cancer in rheumatic diseases[J].Clinical and experimental rheumatology, 2014, 32(6): 839-847.
[8] Francescone R, Hou V, Grivennikov SI. Microbiome, inflammation, and cancer [J]. Cancer Journal, 2014, 20(3):181-189.
[9] Wolfe F. Lymphoma in rheumatoid arthritis: the effect of methotrexate and antitumor necrosis factor therapy in 18, 572 patients[J]. Arthritis and Rheumatism, 2004, 50(6): 1740-1751.
[10] Shankaran V, Ikeda H, Bruce AT, et al. IFN gamma and lympho cytesprevent primary tumour development and shape tumour immunogenicity. Nature, 2001, 410 (6832): 1107-1111.
[11] Marmur R, Kagen L. Cancer associated neuromusculo-skeletal syndromes. Recognizing the rheumatic-neoplas-tic connection[J]. Postgrad Med, 2002, 111 (4): 95-98, 101-102.
[12] Simon TA, Thompson A, Gandhi KK, etal. Incidenceof malignancy in adult patients with rheumatoid arthritis: A meta-analysis[J] .Arthritis Res Ther, 2015, 17: 212.
[13] Fang YF, Wu YJ, Kuo CF, et al. Malignancy in dermatomyositis and polymyositis: analysis of 192 patients[J]. Clinical Rheumatology, 2016, 35(8): 1977- 1984.
[14] Abu Shakra M, Buskila D, Ehrenfeld M, et al. Cancer and autoimmunity: autoimmune and rheumatic feature in patients with malignancies[J]. Ann Rheum Dis 2001, 60: 433-440.
[15] Yang Z, Lin F, Qin B, etal.Polymyositis/dermatomyositis and malignancy risk: a metaanalysis study[J]. The Journal of Rheumatology, 2015, 42(2): 282-291.
[16] Lazarus MN, Robinson D, Mak V, et al. Incidence of cancer in a cohort of patients with primary Sjgren's syndrome[J]. Rheumatology (Oxford), 2006, 45: 1012- 1015．
[17] Weng MY, Huang YT, Liu MF, et al. Incidence of cancer in a nationwide population cohort of 7852 patients with primary Sjgren's syndrome in Taiwan [J]. Ann Rheum Dis, 2012, 71:524-527.
[18] Sela O, Shoenfeld Y. Cancer in autoimmune diseases.Semin Arthritis, 1988, 18: 77-86.
[19] Bernatsky S, Boivin JF, Joseph L, et al. An international cohort study of cancer in SLE[J]. Arthritis Rheum 2005,52:1481-1490.
Copyright (c) 2023 Yingjie Zhang, Haipeng Xie, Minghua Xu, Biao Zhang, Yanhui Jia, Xin Zhang
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors submitting to USP journals agree to publish their manuscript under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0) where authors agree to allow third parties to share their work (copy, distribute, transmit) and to adapt it, under the condition that the authors are given credit, and that in the event of reuse or distribution, the terms of this license are made clear
Authors retain copyright of their work, with first publication rights (online and print) granted to Universe Scientific Publishing or the owner of the journal in question.
